Search results for "PROGRESS"

showing 10 items of 1620 documents

Nonsurgical treatments for primary liver carcinoma in elderly patients: a 12-year retrospective study

2013

Introduction: Cancer is a leading cause of death. 70 percent of cases develop over the age of 65. Although a few patients with metastatic cancer are potentially resectable for cure (particularly those with isolated metastases), treatment for most patients is palliative and generally consists of systemic chemotherapy asoociated to target therapy. Objectives: To evaluate efficacy, safety and outcome of the addition of bevacizumab to chemotherapy in advanced cancer in elderly patients, a prospective study was carried on the last four years at Gonesse Hospital Group. Methods: Patients older than 65year with advanced metastatic (Stage IV) cancer (fourteen colorectal carcinoma, five breast carcin…

medicine.medical_specialtyBevacizumabbusiness.industryColorectal cancerCancerRetrospective cohort studymedicine.diseaseSurgeryOncologyTolerabilityInternal medicinemedicineGeriatrics and GerontologyProspective cohort studybusinessProgressive diseasemedicine.drugCause of deathJournal of Geriatric Oncology
researchProduct

Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (I…

2021

Objectives Clinical staging is widely used in medicine to map disease progression, inform prognosis and guide treatment decisions; in psychiatry, however, staging remains a hypothetical construct. To facilitate future research in bipolar disorders (BD), a well-defined nomenclature is needed, especially since diagnosis is often imprecise with blurred boundaries, and a full understanding of pathophysiology is lacking. Methods Under the auspices of the International Society of Bipolar Disorders, a Task Force of international experts was convened to review, discuss, and integrate findings from the scientific literature relevant to the development of a consensus staging model and standardize a t…

medicine.medical_specialtyBipolar DisorderConsensusHeterogeneous groupTask forceAdvisory CommitteesDisease progressionScientific literaturePrognosisInternational Standard Bibliographic Descriptionmedicine.diseaseTerminologyPsychiatry and Mental healthSDG 3 - Good Health and Well-beingDisease ProgressionmedicineHumansNarrative reviewMedical physicsBipolar disorderPsychologyBiological PsychiatryBipolar Disorders
researchProduct

Progression of Gastric Acid Production in Preterm Neonates: Utilization of In-vitro Method

2018

Background: There have been limited studies done regarding ability to produce gastric acid in preterm infants. Most studies have used in vivo method of assessing gastric pH. Objectives: The objectives of the study was to assess the feasibility of using an in vitro method of measuring gastric pH in babies ≤ 28 weeks gestational age (GA) and determine whether changes in gastric pH differ with gestational age, mode of delivery, and use of antenatal steroids. Design/Methods: Prospective study that enrolled extremely low birth weight (ELBW) babies. Gastric aspirate was collected before feeding. In vitro testing of gastric aspirates for pH were done on days of life 1, 3, 5, 7, 14, and 28 by using…

medicine.medical_specialtyBirth weightCoefficient of variationInvitro methodGastroenterologypH meterprogression of acidity03 medical and health sciences0302 clinical medicine030225 pediatricsInternal medicinemedicinepreterm infantsProspective cohort studygastric pHbusiness.industrylcsh:RJ1-570Gestational ageRepeated measures designlcsh:PediatricsLow birth weight030220 oncology & carcinogenesisPediatrics Perinatology and Child HealthGastric acidrefluxmedicine.symptombusinessFrontiers in Pediatrics
researchProduct

T1HG Bladder Tumours: So Many Papers, Do We Need Them? Yes, We Do!

2009

“How many roads a man must walk on….” and how many papers we must read and write… to put down the final word on the appropriate management of high risk NMI-BC. Although it is more than 20 years that we take notice of promises on biological markers predictive of the behaviour of NMI-BC, till today we can only base our decisions on clinical and pathological data. Consequently, we need exchange of experiences and reports on the outcome of these patients. The aim of the treatment of T1 bladder tumours is to minimize mortality while assuring reduced morbidity and good quality of life. A conservative approach is, obviously, not applicable to all T1HG tumours. We need to identify unequivocal selec…

medicine.medical_specialtyBladder cancerNoticebusiness.industryUrologyGeneral surgerymedicine.diseaseResectionQuality of lifeConcomitantBladder cancer T1 high grade G3 cystectomy conservative treatmentmedicineProper treatmentProgression ratebusinessEuropean Urology
researchProduct

Hereditary angioedema: an update on causes, manifestations and treatment.

2019

Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway. Since laryngeal oedema can be life-threatening as a result of asphyxiation, correct diagnosis and management of hereditary angioedema is vital. Hereditary angioedema attacks are mediated by bradykinin, the production of which is regulated by C1-INH. Hereditary angioedema therapy relies on treatment of acute attacks, and short- and long-term prophylaxis. Acute treatment options include C1-INH concentrate, icatibant and ecallantide. Self-administration of treatment is recomm…

medicine.medical_specialtyBradykinin03 medical and health sciences0302 clinical medicineimmune system diseasesmedicineHumanscardiovascular diseases030212 general & internal medicineskin and connective tissue diseasesHereditary Angioedema Types I and IIbusiness.industryGenetic disorderfood and beveragesGeneral Medicinemedicine.diseaseDermatologyC1 esterase030228 respiratory systemHereditary angioedemaFactor XIIDisease ProgressionQuality of LifeKallikreinsbusinessPeptidesComplement C1 Inhibitor ProteinBritish journal of hospital medicine (London, England : 2005)
researchProduct

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma

2007

Tumor recurrence is a major problem after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). In 60 patients OLT was performed for HCC after pretreatment by repeated transarterial chemoembolization (TACE). Forty-four recipients exceeded the Milan criteria. Recurrence-free 5-year survival was 65.2% and 5-year freedom from recurrence was 73.2%. During the waiting time, 14 patients experienced minimal change, which did not fulfill the definition of tumor progression according to official oncological criteria. Five-year freedom from recurrence among patients with stable compared with progressive disease was 93.3% versus 28.1%, respectively (P = .0001). A stri…

medicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentLiver transplantationMilan criteriaGastroenterologyDisease-Free SurvivalRecurrenceInternal medicinePreoperative CaremedicineHumansEmbolizationChemoembolization TherapeuticTransplantationbusiness.industryPatient SelectionLiver Neoplasmsmedicine.diseaseSurvival AnalysisLiver TransplantationSurgeryTransplantationTumor progressionHepatocellular carcinomaSurgerybusinessLiver cancerProgressive diseaseTransplantation Proceedings
researchProduct

Expression of Wild-Type and Variant Estrogen Receptor Alpha in Liver Carcinogenesis and Tumor Progression.

2011

Although estrogen receptors (ERs) are expressed in human hepatocellular carcinoma (HCC), several clinical trials have failed to demonstrate the efficacy of antiestrogen treatment in HCC patients. Recently, the identification of several ER splicing variants has enlightened the complex nature of estrogen signaling in peripheral tissues; this may help understanding estrogen role in either nontumoral or malignant nonclassical target organs, including liver. In this work we have investigated mRNA expression of wild-type and splice variants of ERα in nontumoral, cirrhotic, and malignant human liver, as well as in HCC cell lines, using an exon-specific reverse transcription polymerase chain reacti…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEstrogen receptorBiologyBiochemistryAromataseCell Line TumorInternal medicineGene OrderGeneticsmedicineHumansRNA MessengerneoplasmsMolecular BiologyLiver NeoplasmsEstrogen Receptor alphaWild typeExonsHep G2 Cellsmedicine.diseaseAntiestrogenGene Expression Regulation NeoplasticReverse transcription polymerase chain reactionAlternative SplicingCell Transformation NeoplasticEndocrinologyLiverEstrogenTumor progressionHepatocellular carcinomaCancer researchMolecular MedicineEstrogen receptor alphaLiver carcinogenesis Estrogen receptors tumor progressionBiotechnology
researchProduct

Expert opinion on managing chronic HCV in patients with cardiovascular disease

2018

International audience; Extrahepatic manifestations of chronic HCV infection include cardiovascular diseases and an increase in cardiovascular mortality. The pathogenic mechanisms by which HCV contributes to cardiovascular disease are not well defined, however, it is likely that systemic inflammation, and the promotion of other metabolic diseases are involved. In this Review, the evidence for HCV infection as a non-traditional risk factor for cardiovascular disease is evaluated. Furthermore, practical advice to evaluate cardiovascular disease risk and disease in chronic hepatitis C patients are included for help in daily clinical practice. Despite the advances in therapies for the treatment…

medicine.medical_specialtyCardiotonic AgentsHepacivirusDisease030204 cardiovascular system & hematologySystemic inflammationAntiviral Agents03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesOdds RatioHumansMedicineDrug InteractionsPharmacology (medical)In patient030212 general & internal medicineRisk factorIntensive care medicineExpert TestimonyCardiovascular mortalityInflammationPharmacologybusiness.industryDisease progressionDisease ManagementHepatitis C Chronic3. Good healthInfectious DiseasesCardiovascular DiseasesExpert opinionPractice Guidelines as TopicDisease riskmedicine.symptombusiness
researchProduct

Primary Biliary Cholangitis: advances in management and treatment of the disease

2017

Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10Â year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. Ursodeoxycholic acid is the only treatment available today, b…

medicine.medical_specialtyCholagogues and CholereticsCirrhosisPrimary Biliary CholangitisCholangitisDiseaseChenodeoxycholic AcidGastroenterologyEnd Stage Liver Disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePrimary biliary cirrhosisDuctopeniaAlkaline phosphatase; Budesonide; Fibrates; Obeticholic acid; Ursodeoxycholic acid; Hepatology; GastroenterologyMED/12 - GASTROENTEROLOGIAInternal medicineAlkaline phosphatasemedicineHumansFibrateSettore SECS-P/01 - Economia PoliticaBudesonideCholestasisHepatologyAlkaline phosphatase; Budesonide; Fibrates; Obeticholic acid; Ursodeoxycholic acidbusiness.industryGastroenterologyObeticholic acidHepatologymedicine.diseaseUrsodeoxycholic acidchemistryUrsodeoxycholic acid030220 oncology & carcinogenesisObeticholic acidDisease Progression030211 gastroenterology & hepatologyDrug Therapy CombinationbusinessFibratesbiologicalRare diseasemedicine.drug
researchProduct